Continuing its active engagement with the COST Action PerMediK network, Delta4 participated in the 6th Management Committee Meeting and Action Workshop held in Lisbon, Portugal ...
Delta4 Reflects on a Milestone BIO-Europe Spring 2025 in Milan Delta4 is pleased to share highlights from this year’s BIO-Europe Spring 2025, held in Milan, ...
Vienna, Austria – January 31th, 2025 – Delta4, a leader in AI-driven drug discovery and indication expansion, is proud to announce that it has been ...
Delta4 is proud to announce its participation in two significant EU Horizon research projects: PICKED (Personalized Medicine in Chronic Kidney Disease) and PROMOTE (Prostate Cancer ...
Delta4 is honored to have been featured in a recent article by Finanz und Wirtschaft, highlighting our pioneering work in AI-driven drug repurposing. The article ...
The term “knowledge graph” describes the process of storing data in a graph-structured topology. A graph database consists of three main elements: nodes, edges, and ...
Nephrotic Syndrome affects millions globally, presenting a significant health burden with its hallmark symptoms of severe proteinuria and edema. The quest for advanced treatments underscores ...
We are delighted to announce that Dr. Klaus Kratochwill, CSO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are looking forward to attending the ...
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to comprehensively understand and broaden the ...
We are thrilled to announce that Delta4 will be in attendance at this year’s RExPO23, a landmark event in the realm of Systems Medicine, Artificial ...
We are honored to announce that our publication on the computational drug repositioning of clopidogrel has been highlighted in the Reactome research spotlight. This notable ...
We are thrilled to announce that our journal article, titled “OntoloViz: a GUI for interactive visualization of ranked disease or drug lists using the MeSH ...
Delta4, a digital drug discovery company, identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS) using their Hyper-C AI software platform. The anti-platelet drug ...
We are incredibly proud to share that our esteemed CEO, Kurt Herpel, has recently been profiled in Insightscare Magazine. In the article titled “Kurt Herpel: ...
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced ...
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital drug development company, today announce ...
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and genetic background. FSGS patients often ...
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology industry. What is Bio-Europe? The ...
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced ...
We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings to Delta4 a deep financial ...
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified in Current Discovery Programs Ready ...
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed four patent applications for compounds ...
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in our drug discovery programs in ...
Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life ...
The 20th Annual Biotech in Europe (BEF) Forum is recognized as the leading international Stage for those interested in investing and partnering in the biotech ...
With over 1,500 attendees from 50+ countries, the 2020 edition of the World Orphan Drug Congress USA was held online on August 24-26. The conference ...
Delta4 Announces Results Achieved with Drug Discovery Platform Vienna, Europe (June 2, 2020) – Delta4, a biotech company using its proven digital drug discovery platform ...
The global crisis caused by the SARS-Cov2 outbreak requires rapidly applicable therapeutics. Available approved drug substances represent one of the more realistic paths to clinical ...
What Is It? Biotech Showcase™ is an investor conference during JPM 2020, devoted to providing private and public biotech companies and life sciences companies with ...
Delta4 Reflects on the 2020 LSX Investival Showcase: A Landmark Event in Life Sciences Innovation In November 2020, the prestigious Waldorf Hilton Hotel in London ...
Delta4’s Participation at the 19th Annual Biotech in Europe Forum: A Landmark Experience Delta4 was honored to attend the 19th Annual Biotech in Europe Forum ...
